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Abstract
Molecular alterations compromising key metabolic pathways are
poorly understood in sporadic frontotemporal lobar degeneration
with TDP-43 pathology (sFTLD-TDP). Whole-transcriptome array,
RT-qPCR validation, gel electrophoresis, and Western blotting, and
mitochondrial electron transport chain (ETC) activity were compar-
atively examined in frontal cortex (area 8) of 16 sFTLD-TDP cases
and 14 controls. Assessment of 111 genes by RT-qPCR showed de-
regulation of 81 genes linked to neurotransmission and synapses,
neuronal architecture, cytoskeleton of axons and dendrites, vesicle
trafficking, purines, mitochondria, and energy metabolism in
sFTLD-TDP. Western blotting studies disclosed downregulation of
several mitochondrial subunits encoded by genomic DNA and MT-
CO1 encoded by the mitochondrial DNA. Mitochondrial ETC
activity of complexes I, IV, and V was decreased in sFTLD-TDP.
These findings provide robust information about downregulation
of genes involved in vital biochemical pathways and in synaptic
neurotransmission which may help to increase understanding about
the biochemical substrates of clinical manifestations in sFTLD-TDP.
Key Words: Energy metabolism, Frontotemporal lobar degeneration,
Mitochondria, Neurotransmission, Purines, Synapses, TDP43.
INTRODUCTION
Frontotemporal dementia is a progressive neurological
disorder characterized by deterioration of personality, behav-
ior, language, and cognition, with marked individual varia-
tions, and in the majority of patients is due to frontotemporal
lobar degeneration (FTLD). This term stresses the progressive
loss of neurons in the frontal and temporal lobes as the cause
of the principal neurological symptoms. FTLD is not a unique
disease but covers several unrelated conditions: 1) FTLD-tau
is identified by the abnormal tau deposition in neurons and
glial cells, which in turn encompasses sporadic and genetic
forms associated with mutations in MAPT, the gene coding for
protein tau; and 2) FTLD-U, which is characterized by the
presence of intraneuronal ubiquitin-immunoreactive inclu-
sions. Subsequent studies have demonstrated the heterogene-
ity of FTLD-U, including FTLD-TDP-43 proteinopathy,
FTLD-FUS proteinopathy, and FTLD-UPS, lacking TDP-43
and FUS inclusions (1–3).
FTLD-TDP-43 proteinopathy (FTLD-TDP) is clinically
manifested by behavioral-dysexecutive disorder, primary pro-
gressive aphasia and/or motor disorders including motor neu-
ron disease; macroscopically, by frontal and temporal atrophy,
commonly symmetrical, variable involvement of the basal gan-
glia and substantia nigra; and microscopically, by neuron loss
in the cerebral cortex, microvacuolation in the upper cortical
layers, astrogliosis, and TDP-43-immunoreactive inclusions in
the nucleus and/or cytoplasm of neurons and oligodendocytes,
and in neuropil threads (1–3). Some cases are sporadic
(sFTLD-TDP) whereas other are genetic, often familial
(fFTLD-TDP) and linked to mutations in different genes in-
cluding GRN (progranulin), C9ORF72 (chromosome 9 open
reading frame 72), TARDP (TAR DNA-binding protein), VCP
(valosin-containing protein), CHMBP2 (charged multivesicu-
lar body protein 2), and UBQLN (ubiquilin 2), among others
(4–6). Excepting progranulin, mutations of any of the other
genes may also be causative of amyotrophic lateral sclerosis
(ALS), thus suggesting ALS/FTLD-TDP within the same
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disease spectrum (7–9). The presence of TDP-43 inclusions in
ALS together with the characteristics of TDP-43, which is
phosphorylated, ubiquitinated, and truncated at the C-terminal
in both conditions (10), argues in favor of these bounds.
FTLD-TDP has been subclassified into 4 different neu-
ropathologic subgroups that roughly correlate with certain
clinical symptoms and genetic substrates although with low
predictive value (11, 12). Type A is characterized by numer-
ous neuronal cytoplasmic inclusions (NCIs) and dystrophic
neurites (DNs), and variable number of neuronal nuclear
inclusions (NIIs) predominating in the upper cortical layers.
Type B is delineated by numerous NCIs in the upper and inner
cortical layers, and low numbers of DNs and NIIs. Type C is
defined by predominant DNs in the upper cortical layers and
rare NCIs and NIIs. Type D is characterized by predominance
of NIIs, and rare NCIs and DNs (1, 11, 12).
The study of human brain tissue has been useful to un-
veil additional molecular alterations in FTLD-TDP (13). Com-
plementary information has been obtained using proteomics
and transcriptomics in a limited number of FTLD-TDP
subtypes including those linked with GRN and C9Orf72 muta-
tions, and atypical FTLD-TDP cases (14–17). Gene expres-
sion profile has also been recently described in the frontal
cortex area 8 in ALS (18) and in different brain regions in spo-
radic ALS and ALS linked to C9Orf72 mutations (19). How-
ever, the molecular pathology of metabolic pathways,
mitochondria and energy metabolism, synapses, and neuro-
transmission has not been studied in sFTLD-TDP. The present
study was aimed at analyzing gene expression in frontal cortex
area 8 in a series of sFTLD-TDP in parallel with controls in or-
der to gain understanding about vulnerable pathways which
can explain pathogenic aspects of the disease.
MATERIALS ANDMETHODS
Human Cases
Brain samples were obtained from the Brain Banks of
the Institute of Neuropathology HUB-ICO-IDIBELL Biobank
and the Hospital Clinic-IDIBAPS Biobank following the
guidelines of the Spanish legislation on this matter and the ap-
proval of the local ethics committees. The postmortem interval
between death and tissue processing was between 2 and
18 hours. One hemisphere was immediately cut into 1-cm-
thick coronal sections, and selected brain areas were rapidly
dissected, frozen on metal plates over dry ice, placed in indi-
vidual air-tight plastic bags and stored at80C until use. The
other hemisphere was fixed by immersion in 4% buffered for-
malin for 3 weeks. The neuropathological study in control and
FTLD-TDP cases was carried out on 20 selected 4-lm-thick
dewaxed paraffin sections of representative regions of the
frontal, temporal, parietal, motor, primary visual, anterior cin-
gulate and entorhinal cortices, hippocampus, amygdala, basal
forebrain, caudate, putamen, globus pallidus, thalamus, mid-
brain, pons, medulla oblongata, cerebellar vermis, hilus, and
cerebral white matter. These were stained with hematoxylin
and eosin, Klu¨ver-Barrera, or processed for immunohisto-
chemistry for microglia (Iba-1, Wako, Richmond, VA), glial
acidic protein ([GFAP], Dako, Gostrup, Denmark), b-amyloid
(Dako, clone 6F/3D), phospho-tau (Thermo Scientific, Rock-
ford, IL, clone AT8), a-synuclein (Novocastra, Newcastle,
UK, clone KM51), TDP-43 (Abnova, Taipei, Taiwan, clone
2E2-D3), ubiquitin (Dako, Polyclonal Rabbit), and p62 (BD
Biosciences, San Jose, Purified Mouse Anti-p62 LCK ligand)
using EnVisionþSystem peroxidase (Dako), and diaminoben-
zidine and H2O2. FTLD-TDP was diagnosed following well-
established criteria: frontotemporal atrophy, loss of neurons
and variable spongiosis in the upper cortical layers, astrocytic
gliosis, and presence of TDP-43-immunoreactive inclusions in
neurons and dendrites (NCIs, NIIs, and DNs) (1, 11). The
whole series included 16 sporadic cases of FTLD-TDP
(71.66 9.6 years; 11 men and 3 women), and 14 control cases
(66.56 8.8 years; 8 men and 6 women). The postmortem de-
lay varied from 2 hours and 15 minutes to 18 hours
(5.46 4.0) in the control group, and between 3 hours and
40 minutes and 16 hours (7.56 3.9) in the sFTLD-TDP
group. Patients with associated pathologies of the nervous sys-
tem, excepting early stages of neurofibrillary tangle pathology
and mild small blood vessel disease, were not included. Age-
matched control cases had not suffered from neurologic and
psychiatric disorders and did not show alterations other than
those permitted in diseased cases. Regarding TDP types: 11
cases were categorized as type A, 1 as type B, and 4 as type C.
A summary of cases is shown in Table 1.
Biochemical studies were carried out in fresh-frozen
frontal cortex area 8. Special care was taken to assess premor-
tem and postmortem factors that might interfere with RNA
processing and protein integrity (20). For this reason, all the
samples were used in the study of RNA expression because
RNA integrity values were suitable for RNA study, whereas
10 samples per group were used for gel electrophoresis and
Western blotting of samples showing a preserved band pattern
after Coomassie Blue staining. The same 10 cases per group
were used in the study of mitochondrial enzymatic activities.
Cases excluded were neoplastic diseases affecting the nervous
system, metabolic syndrome, hypoxia, and prolonged agonic
state (such as those occurring in intensive care units), as well
as cases with infectious, inflammatory, and autoimmune dis-
eases, either systemic or limited to the nervous system.
Assessed samples did not bear C9ORF72 mutations (21). No
other FTLD-TDP-related genes were systematically analyzed.
RNA Purification
RNA from frozen frontal cortex area 8 was extracted fol-
lowing the instructions of the supplier (RNeasy Mini Kit, Qia-
gen, Hilden, Germany). RNA integrity and 28S/18S ratios
were determined with the Agilent Bioanalyzer (Agilent Tech-
nologies, Inc., Santa Clara, CA). RNA integrity values are
shown in Table 1. Samples were treated with DNase digestion,
and RNA concentration was evaluated using a NanoDrop
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
Whole-Transcriptome Array and RT-qPCR
Validation
Selected samples were analyzed by microarray hybridi-
zation with Human Clariom D Assay kit and GeneChip WT
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Plus Reagent Kit and microarray 7000 G platform from Affy-
metrix (Santa Clara, CA). Preprocessing of raw data and statis-
tical analyses were performed using bioconductor packages in
R programming environment for genes (22). Complementary
DNA (cDNA) was obtained using High-Capacity cDNA Re-
verse Transcription kit (Applied Biosystems, Foster City, CA)
following the protocol of the supplier. Parallel reactions for
each RNA sample were run in the absence of MultiScribe Re-
verse Transcriptase to assess lack of contamination of geno-
mic DNA. Gene selection was based upon their values using a
test for differential expression between 2 classes (Student
t-test). Selected genes differentially expressed showed an ab-
solute logarithm of fold change >0.5 combined with a p val-
ue 0.01. Table 2 shows identification numbers and names of
selected TaqMan probes. Most of the tested probes corre-
sponded to deregulated genes as revealed by microarrays; the
remainder was selected to assess other key genes of the altered
pathways that were not identified as deregulated in the arrays.
TaqMan RT-qPCR assays were performed in duplicate for
each gene on cDNA samples in 384-well optical plates using
TABLE 2. Gene Symbols and TaqMan Probes Used in Frontal
Cortex Area 8 Including Normalization Probes (GUS-b)
Gene TaqMan assay
ABLIM2 Hs00402222_m1
ACTLB6 Hs00211827_m1
ACTR3B Hs01051213_m1
ACTR3C Hs03988416_m1
AK1 Hs00176119_m1
AK2 Hs01123132_g1
AK5 Hs00952786_m1
AK7 Hs00330574_m1
AMIGO1 Hs00324802_s1
APOOL Hs00922772_g1
APRT Hs00975725_m1
ARPC5L Hs00229649_m1
ATP2B3 Hs00222625_m1
ATP2B4 Hs00608066_m1
ATP4A Hs00167575_m1
ATP5A1 Hs00900735_m1
ATP5B Hs00969569_m1
ATP5H Hs01046892_gH
ATP5L Hs00538946_g1
ATP5O Hs00426889_m1
ATP6D Hs00371515_m1
ATP6V1A Hs01097169_m1
BSN Hs01109152_m1
C9ORF72 Hs00376619_m1
CALB1 Hs01077197_m1
CEP126 Hs01573778_m1
CEP41 Hs00363344_m1
CKAP2 Hs00217068_m1
COA6 Hs01372973_m1
CORO2A Hs00185610_m1
COX7AL Hs00190880_m1
DDN Hs00391784_m1
DGUOK Hs00176514_m1
ENTPD1 Hs00969559_m1
ENTPD2 Hs00154301_m1
ENTPD3 Hs00928977_m1
FASTKD2 Hs01556124_m1
FRMPD4 Hs01568794_m1
GABBR2 Hs01554996_m1
GABRA1 Hs00971228_m1
GABRA2 Hs00168069_m1
GABRA3 Hs00968130_m1
GABRB2 Hs00241451_m1
GABRB3 Hs00241459_m1
GABRD Hs00181309_m1
GABRG2 Hs00168093_m1
GABRG3 Hs00264276_m1
GAD1 Hs01065893_m1
GAP43 Hs00967138_m1
GDAP1L1 Hs00225209_m1
GFAP Hs00909240_m1
GRIA1 Hs00181348_m1
GRIN2A Hs00168219_m1
(continued)
TABLE 1. Summary of the 30 Cases Analyzed
Case Sex Age Diagnosis PMD RIN TDP43
1 M 66 Control 18 h 0 min 6.4 –
2 M 61 Control 3 h 40 min 7.0 –
3 M 62 Control 5 h 45 min 5.0 –
4 M 74 Control 6 h 40 min 7.2 –
5 M 65 Control 5 h 15 min 6.8 –
6 F 64 Control 2 h 15 min 5.0 –
7 M 63 Control 8 h 05 min 7.1 –
8 F 79 Control 3 h 35 min 6.8 –
9 F 67 Control 5 h 20 min 6.2 –
10 M 70 Control 3 h 45 min 7.2 –
11 M 52 Control 4 h 40 min 7.2 –
12 F 52 Control 5 h 45 min 5.1 –
13 F 82 Control 7 h 35 min 5.2 –
14 F 74 Control 2 h 45 min 5.7 –
15 M 76 sFTLD-TDP 5 h 0 min 6.2 A
16 F 82 sFTLD-TDP 3 h 40 min 6.4 A
17 M 71 sFTLD-TDP 4 h 0 min 6.1 A
18 F 77 sFTLD-TDP 16 h 0 min 6.9 C
19 M 73 sFTLD-TDP 5 h 0 min 6.7 C
20 M 63 sFTLD-TDP 9 h 30 min 5.0 A
21 F 77 sFTLD-TDP 7 h 39 min 7.0 A
22 M 65 sFTLD-TDP 13 h 0 min 7.4 A
23 F 88 sFTLD-TDP 6 h 30 min 5.4 A
24 M 59 sFTLD-TDP 8 h 0 min 7.4 A
25 M 58 sFTLD-TDP 4 h 0 min 7.3 A
26 M 56 sFTLD-TDP 8 h 0 min 5.0 A
27 F 84 sFTLD-TDP 6 h 0 min 5.9 B
28 M 78 sFTLD-TDP 7 h 15 min 6.7 C
29 M 66 sFTLD-TDP 5 h 15 min 7.2 A
30 M 74 sFTLD-TDP 15 h 0 min 6.4 C
sFTLD-TDP, sporadic frontotemporal lobar degeneration-TDP; F, female; M, male;
PM, postmortem delay; RIN, RNA integrity number; TDP43, histological types of
FTLD-TDP based on TDP-43-immunoreactive inclusions (see Materials and Methods).
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an ABI Prism 7900 Sequence Detection system (Applied Bio-
systems, Life Technologies, Waltham, MA). For each 10lL
TaqMan reaction, 4.5lL cDNA was mixed with 0.5lL 20
TaqMan Gene Expression Assays and 5lL of 2 TaqMan
Universal PCR Master Mix (Applied Biosystems). Values of
GUS-b were used as internal controls for normalization (23).
The parameters of the reactions were 50C for 2 minutes,
95C for 10 minutes, and 40 cycles of 95C for 15 seconds and
60C for 1 minute. Finally, capture of all TaqMan PCR data
used the Sequence Detection Software (SDS version 2.2.2,
Applied Biosystems). For the data analysis, threshold cycle
(CT) values for each sample were processed to obtain the dou-
ble delta CT (DDCT) values. First, delta CT (DCT) values
were calculated as the normalized CT values of each target
gene in relation to the CT of endogenous controls GUS-b.
Then, DDCT values were obtained from the DCT of each sam-
ple minus the mean DCT of the population of control samples.
Results were analyzed using the Student t-test.
RNA Purification, Retrotranscription Reaction,
and RT-qPCR for Detection of 3R and 4R Tau
Isoforms
Tau mRNA isoforms were assessed by using SYBR
green quantitative RT-qPCR; 1000 ng of total RNA was used
as a template. cDNA samples obtained from the retrotranscrip-
tion reaction were diluted 1:20 and duplicate SYBR green
PCR assays for each gene were performed. For each reaction,
2.5mL of cDNA was mixed with 1.25mL of forward primer
10lM, 1.25mL reverse primer 10lM, and 5mL of PowerUp
SYBR Green Master Mix (Applied Biosystems). The reactions
were performed following the parameters: 50C for 2 minutes,
95C for 10 minutes, and 40 cycles at 95C for 15 seconds and
at 60C for 1 minute. SYBR green PCR data were captured us-
ing the Sequence Detection Software (SDS version 2.2).
3Rtau forward primer sequence: GTCCGTACTCCACC-
CAAGTC; 3Rtau reverse: GTTTGTAGACTATTTG-
CACCTTC; 4Rtau forward: GGCGGGAAGATGCAGATAA
TTAAT; 4Rtau reverse: GTAGACTATTTGCACACTGCC.
Parallel assays for each sample were carried out using primers
for b-glucuronidase (GUS-b), forward: GTCTGCGGCA
TTTTGTCGG; reverse: CACACGATGGCATAGGAATGG
as endogenous controls. Mean fold-change values of each ex-
perimental group were analyzed by 1-way ANOVA test with
post hoc Tukey by using GraphPad Prism version 5.01 (La
Jolla, CA) and Statgraphics Statistical Analysis and Data Vi-
sualization Software version.1 (Warrenton, VA).
TABLE 2. Continued
Gene TaqMan assay
GRIN2B Hs01002012_m1
GRM5 Hs00168275_m1
GULP1 Hs01061497_m1
GUS-b Hs00939627_m1
HOMER1 Hs01029333_m1
KIF17 Hs00325418_m1
KLC2 Hs03988192_m1
LRRC6 Hs00917168_m1
MAP1A Hs00357973_m1
MAST3 Hs00390797_m1
MCU Hs00293548_m1
MICU3 Hs01028469_m1
MRPL1 Hs00220322_m1
MRPS35 Hs00950427_m1
MTIF2 Hs01091373_m1
MTX3 Hs01372688_m1
NDUFA10 Hs01071117_m1
NDUFA2 Hs00159575_m1
NDUFA5 Hs00916783_m1
NDUFAF2 Hs02380072_u1
NDUFAF6 Hs00901870_m1
NDUFB10 Hs00605903_m1
NDUFB5 Hs00159582_m1
NDUFB8 Hs00428204_m1
NDUFS8 Hs00159597_m1
NME1 Hs02621161_s1
NME3 Hs01573874_g1
NME4 Hs00359037_m1
NME7 Hs00273690_m1
NRN1 Hs00213192_m1
NT5C Hs00274359_m1
NUDT1 Hs00159343_m1
PAK5 Hs00379318_m1
PCLO Hs00382694_m1
PLP1 Hs00166914_m1
PNP Hs01002926_m1
POLR3B Hs00932002_m1
PRUNE Hs00535700_m1
PSD Hs00160539_m1
RMND1 Hs01012514_m1
RMND2 Hs04187037_m1
RND1 Hs00205507_m1
SDHB Hs00268117_m1
SLC17A7 Hs00220404_m1
SLC1A1 Hs00188172_m1
SLC1A2 Hs01102423_m1
SLC25A1 Hs01105608_g1
SLC25A11 Hs00185940_m1
SLC25A23 Hs01012756_m1
SLC32A1 Hs00369773_m1
SNAP25 Hs00938957_m1
SNAP91 Hs01097941_m1
SYN1 Hs00199577_m1
SYP Hs00300531_m1
(continued)
TABLE 2. Continued
Gene TaqMan assay
SYT1 Hs00194572_m1
TARDBP Hs00606522_m1
TOMM70 Hs00207896_m1
UQCR11 Hs00907747_m1
UQCRB Hs00559884_m1
VAMP1 Hs04399177_m1
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Gel Electrophoresis and Western Blotting
Frozen samples of the frontal cortex area 8 were homog-
enized in RIPA lysis buffer (50 mM Tris/HCl buffer, pH 7.4
containing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM PMSF,
protease, and phosphatase inhibitor cocktails; Roche Molecu-
lar Systems, Pleasanton, CA). Homogenates were centrifuged
at 14 000g for 20 minutes. Protein concentration was deter-
mined with the BCA method (ThermoFisher Scientific). Equal
amounts of protein (12lg) for each sample were loaded and
separated by electrophoresis on 10% sodium dodecyl-sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gels and
transferred onto nitrocellulose membranes (Amersham, Frei-
burg, Germany). Nonspecific binding was blocked by incuba-
tion with 3% albumin in PBS containing 0.2% Tween for
1 hour at room temperature. After washing, membranes were
incubated overnight at 4C with 1 of primary antibodies
(Table 3). Protein loading was normalized using an antibody
against GAPDH (37 kDa, 1:2500, Abcam, Cambridge, UK).
Membranes were then incubated for 1 hour in the appropri-
ate HRP-conjugated secondary antibodies (1:2000, Dako,
Santa Clara, CA). Immunocomplexes were revealed with
chemiluminescence reagent (ECL, Amersham). Densitomet-
ric quantification was carried out with ImageLab v4.5.2 soft-
ware (Bio-Rad, Hercules, CA).
Isolation of Mitochondrial-Enriched Fractions
From Human Brain Tissue
Mitochondria were extracted from frozen frontal cortex
(100 mg) under ice-cold conditions. Tissues were minced in
ice-cold isolation buffer (IB) containing 0.25 M sucrose,
10 mmol/L Tris, and 0.5 mmol/L EDTA, pH 7.4, and then ho-
mogenized and centrifuged at 1000g for 10 minutes. Samples
were homogenized with a micropestle using 10 vol buffer per
mg of tissue and centrifuged at 1000g for 10 minutes at 4C.
The supernatant (S1) was conserved. The pellet was washed
with 2 vol IB and centrifuged under the same conditions. The
last supernatant (S2) was combined with S1, mixed, and centri-
fuged at 10 000g for 10 minutes at 4C, resulting in the
mitochondria-enriched pellet. The supernatant (S3) was dis-
carded and the pellet was washed with 2 volumes IB and centri-
fuged at 10 000g for 10 minutes at 4C, thereby obtaining the
washed mitochondria-enriched pellet. The supernatant (S4) was
discarded and the final pellet was resuspended in 1 vol IB and
stored at 80C. Protein concentration was measured using a
SmartspectTMplus spectrophotometer (Bio-Rad) and the Brad-
ford method (Merck, Darmstadt, Germany). The mitochondrial
enriched fraction was used for mitochondrial enzymatic activi-
ties and for Western blotting. Protein loading (12lg) was nor-
malized with anti-VDAC (1:500, Abcam).
TABLE 3. List of Antibodies Used in Western Blotting
Primary antibody Symbol Source Reference Host WB Dilution
Actin Binding LIM Protein Family Member 2 ABLIM2 Abcam ab100926 Rabbit 1:750
ATP synthase subunit alpha, mitochondrial ATP5 Abcam ab110411 Mouse 1:1000
Calbindin CALB Swant CB-38a Rabbit 1:5000
Chromosome 9 open reading frame 72 C9ORF72 Abcam ab183892 Rabbit 1:500
Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 Abcam ab110411 Mouse 1:1000
Cytochrome c oxidase MT-CO1 Abcam ab110411 Mouse 1:1000
Gamma-aminobutyric acid Receptor Subunit beta-2 GABAARB2 Abcam ab156000 Rabbit 1:500
Gamma-Aminobutyric Acid Type A Receptor Delta Subunit GABRD Abcam ab110014 Rabbit 1:1000
Glial Fibrillary Acidic Protein GFAP Dako Z0334 Rabbit 1:5000
Glutamate (NMDA) receptor subunit epsilon-1 NMDAR2A Abcam ab169555 Rabbit 1:250
Glutamate Decarboxylase 1 GAD1 CellSignaling #5305 Rabbit 1:250
Glyceraldehyde-3-Phosphate Dehydrogenase GAPDH Abcam ab9485 Rabbit 1:2500
Mitochondrial import receptor subunit TOM70 TOMM70 Novus biological NBP1-87863 Rabbit 1:500
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 10 NDUFA10 Antibody BCN GTX114572 Rabbit 1:1000
NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 10 NDUFB10 Antibody BCN 15589-1-AP Rabbit 1:2500
NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8,
mitochondrial
NDUFB8 Abcam ab110411 Mouse 1:1000
NADH dehydrogenase (ubiquinone) iron-sulfur protein 8, mitochondrial NDUFS8 Antibody BCN GTX114119 Rabbit 1:1000
NADH-ubiquinone oxidoreductase chain 1 MT-ND1 Abcam ab181848 Rabbit 1:1000
Postsynaptic density protein 95 PSD-95 Invitrogen 7E3-1B8 Mouse 1:1000
Succinate dehydrogenase (ubiquinone) iron-sulfur subunit, mitochondrial SDHB Abcam ab110411 Mouse 1:1000
Synaptophysin SYN Novocastra NCL-L-SYNAP-299 Mouse 1:1000
Synaptosome Associated Protein 25 SNAP-25 BioLegend SMI81 Mouse 1:1000
Vesicular inhibitory amino acid transporter VGAT Synaptic systems 131 011 Mouse 1:1000
Voltage Dependent Anion Channel 1 VDAC1 Abcam ab15895 Rabbit 1:500
4R TAU 4R TAU Merck-Millipore clone 1E1/A6 Mouse 1:50
3R TAU 3R TAU Merck-Millipore clone 8E6/C11 Mouse 1:500
Phospho-tau Thr181 Thr181 Cell Signalling mAb 12885 Rabbit 1:50
Total Tau Tau 5 Thermo-Fisher AHBOO42 Mouse 1:250
TAR DNA-binding protein 43 TDP-43 Abcam ab154047 Rabbit 1:250
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The activities of mitochondrial complexes I, II, IV, and V
were analyzed using commercial kits following the instructions
of the suppliers (Mitochondrial complex V: Novagen, Merck
Biosciences; and Mitochondrial complex I, II, and IV: Abcam).
Activity of citrate synthase was evaluated as a quantitative en-
zyme marker for the presence of intact mitochondria using com-
mercial kits (Abcam). About 25 lg of mitochondria extract was
loaded into each well. The enzymatic activities for each mito-
chondrial complex were expressed as a rate of milli-optical den-
sities per minute normalized with the citrate synthase activity.
Statistical Analysis
The normality of distribution of fold-change values was
analyzed with the Kolmogorov-Smirnov test. The nonpara-
metric Mann-Whitney test was performed to compare each
group when values did not follow a normal distribution, while
the unpaired t-test was used for normal variables. Statistical
analysis and graphic design were performed with GraphPad
Prism version 5.01 (La Jolla, CA). Results were analyzed with
the Student t-test. Outliers were detected using the GraphPad
software QuickCalcs (p< 0.05). All data were expressed as
mean6 SEM and significance levels were set at *p< 0.05,
**p< 0.01, and ***p< 0.001. Pearson’s correlation coeffi-
cient was used to assess a possible linear association between
2 continuous quantitative variables.
RESULTS
Main Neuropathological Findings
All sFTLD-TDP cases presented variable neuron loss
and microvacuolation in the upper cortical layers, mild
astrocytic gliosis in all layers of the cortex and the presence
of TDP-43-immunoreactive dystrophic neurites mainly in
the upper layers accompanied or not by neuronal cytoplasmic
inclusions. Neuronal intranuclear inclusions were extremely
rare. About 11 cases were categorized as type A, 1 as type B,
and 4 as type C (Table 1; Fig. 1). Type A was characterized
by numerous NCIs and DNs in the upper cortical layers; type
B by numerous NCIs in the upper and inner cortical layers;
and type C by predominant DNs in the upper cortical layers.
p62-immunoreactive inclusions were absent in any brain
region.
Microarray Analysis
All samples had enough quality for subsequent analysis
after quality control analysis. The cofactors age and gender
were not relevant for the analysis. After filtering, 4851 genes
were included in the analysis. The analysis to select differen-
tially expressed genes was based on adjusting a linear model
with empirical Bayes moderation of the variance. The 538 top
variable genes (with nominal p values <0.01 and an absolute
logarithm of the fold change 0.5) were represented in a heat
map to illustrate common and differing gene expression
patterns between control and sFTLD-TDP cases in FC
(Fig. 2A). We identified 425 genes differentially expressed in
sFTLD-TDP compared with controls (5 up and 420 down)
(Fig. 2B). Gene Ontology (GO) database was used to highlight
biological categories of differentially regulated genes. Down-
regulated genes in sFTLD-TDP were involved in neurotrans-
mission and synapsis, neuron architecture, cytoskeleton of
axons and dendrites, vesicle trafficking, purine metabolism,
mitochondria, and energy metabolism (Table 4). Raw data are
FIGURE 1. Examples of TDP-43-immunoreactive inclusions, including thin and thick dystrophic neuritis and cytoplasmic
inclusions in frontal cortex area 8 in sFTLD-TDP. (A–C) Type C; (D, E) Type A; (F) Type B. (A), (B), and (C), cases 18, 19, and
28, respectively; (D) and (E), cases 23 and 25, respectively; (F), case 27. Paraffin sections, hematoxylin counterstaining, scale
bar¼50 lm.
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found in https://www.ebi.ac.uk/arrayexpress/; reference num-
ber fgsubs #218580.
Gene Expression Validation
RT-qPCR was carried out to assess the expression of
111 selected genes; 81 of them were abnormally regulated in
sFTLD-TDP.
TARDBP and C9ORF72, and GFAP
TARDBP and C9ORF72 were significantly decreased in
sFTLD-TDP compared with controls (p¼ 0.05 and p¼ 0.01,
respectively) (Fig. 2A). GFAP expression was increased
(p¼ 0.003) in sFTLD-TDP (Fig. 3A).
Cytoskeleton and Neuron Architecture
The expression of 17 genes was analyzed by RT-qPCR;
12 of them showed decreased expression in sFTLD-TDP
when compared with controls. ABLIM2 (p¼ 0.0001), ACTLB6
(p¼ 0.025), ACTR3B (p¼ 0.002), ACTR3C (p¼ 0.05),
CEP41 (p¼ 0.003), CKAP2 (p¼ 0.017), CORO2A (p¼ 0.05),
KIF17 (p¼ 0.003), MAP1A (p¼ 0.05), MAST3 (p¼ 0.003),
PAK5 (p¼ 0.005), and RND1 (p¼ 0.008) showed a significant
decrease in sFTLD-TDP (Fig. 3B, C).
Synapsis and Neurotransmission
The expression of 36 genes was assessed; 30 of them were
downregulated in sFTLD-TDP. The expression of the following
genes implicated in presynaptic and postsynaptic attachment was
significantly decreased in sFTLD-TDP: DDN (p¼ 0.04),
FRMPD4 (p¼ 0.01), GAP43 (p¼ 0.004), HOMER1
(p¼ 0.000), NRN1 (p¼ 0.004), PCLO (p¼ 0.005), and PSD
(p¼ 0.013). Similarly, 15 genes involved in GABAergic and glu-
tamatergic neurotransmission were downregulated in sFTLD-
TDP: CALB1 (p¼ 0.000), GABBR2 (p¼ 0.033), GABRA1
(p¼ 0.004), GABRA2 (p¼ 0.008), GABRA3 (p¼ 0.000),
GABRB2 (p¼ 0.006), GABRB3 (p¼ 0.002), GABRD
(p¼ 0.024), GABRG2 (p¼ 0.001), GAD1 (p¼ 0.05), GRIA1
(p¼ 0.042), GRIN2A (p¼ 0.048), GRIN2B (p¼ 0.025), GRM5
(p¼ 0.002), SLC1A1 (p¼ 0.02), SLC17A2 (p¼ 0.049), and
SLC32A1 (p¼ 0.025). Finally, a set of genes involved in
synaptic vesicles were significantly deregulated in sFTLD-TDP:
GULP1 (p¼ 0.001), SNAP25 (p¼ 0.006), SNAP91 (p¼ 0.012),
SYN1 (p¼ 0.001), SYP (p¼ 0.035), and SYT1 (p¼ 0.017)
(Fig. 4).
Expression Levels of Genes Involved in Purine
Metabolism
The expression of 18 genes was assessed by RT-qPCR;
9 of them were downregulated. AK5 (p¼ 0.000), AK7
FIGURE 2. (A) Hierarchical clustering heat-map of expression intensities of mRNA array transcripts reflects differential gene
expression profiles in frontal cortex area 8 in controls (red), sFTLD-TDP (blue). Differences are considered statistically significant
at p value0.01 and logFC 0.5. (B) Total number of significantly different expressed genes in sFTLD-TDP versus controls. (C)
Diagram showing deregulated gene clusters in frontal cortex area 8 in sFTLD-TDP compared with controls as revealed by whole
transcriptome arrays.
J Neuropathol Exp Neurol • Volume 0, Number 0, 2018 Gene Expression in sFTLD-TDP
7
Downloaded from https://academic.oup.com/jnen/advance-article-abstract/doi/10.1093/jnen/nly037/4999948
by Washington University School of Medicine Library user
on 23 May 2018
TABLE 4.Main Significant Clusters of Altered Genes in Frontal Cortex Area 8 in sFTLD-TDP
GO Term Count Size Genes Odds ratio p value
Actin filament-based
process
38 186 ABLIM2, ACTN4, ACTR3B, ACTR3C, ADD2, ARHGEF2, ARPC5L, BAG4,
BAIAP2, CACNA2D1, CACNB2, CAP2, CAPZA2, CDK5, CDK5R1, CORO2A,
DNAJB6, EPB41L4B, FGF12, ID1, ITGB1BP1, LIMK1, MEF2C, PACSIN1,
PHACTR1, PIP5K1C, PRKCZ, PTK2B, RND1, SCN1B, SCN2B, SCN3B,
SDAD1, SORBS2, STC1, SYNPO, TPM2, WASF1
1.65 6.74e-03
Action potential 15 43 CACNA1G, CACNA1H, CACNA1I, CACNA2D1, CACNB2, DRD1, FGF12,
GNAQ, KCNA1, PTPN3, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A
3.42 3.74e-04
Alternative mRNA splic-
ing, via spliceosome
5 10 CELF3, CELF4, RBFOX1, RBFOX2, RBFOX3 6.30 6.82e-03
Anterograde transsynaptic
signaling
63 182 AKAP5, AMPH, BAIAP2, BTBD9, CA7, CACNA1G, CACNB1, CACNB2, CADPS,
CADPS2, CDK5, CELF4, CHRM1, CLSTN3, DGKI, DLGAP1, DOC2A, DRD1,
EGR3, FGF12, GABBR2, GABRB3, GABRG2, GFAP, GLRA3, GPR176,
GRIN2A, GRM2, GRM5, GSK3A, HOMER1, HTR4, KCNA1, KCNQ2, KCNQ5,
LRRTM1, LRRTM2, MAPK8IP2, MEF2C, NRXN3, OPRL1, PCDH8,
PIP5K1C, PLK2, PNOC, PRKCG, PRKCZ, PTK2B, RASGRF1, RIMS1,
RPH3A, SCN1B, SCN2B, SLC12A5, SLC17A7, SNAP25, SNAP91, STXBP1,
SYN1, SYNJ1, SYP, SYT1, UNC13A
3.65 1.90e-13
Axon 47 127 AMIGO1, AP1S1, AP3S1, ATL1, ATP1A3, BLOC1S2, CCK, CDK5, CDK5R1,
CHRM1, DAGLA, DGKI, ELK1, GABRA2, GABRG2, GAP43, GRM2,
HOMER1, HPCA, INPP5F, KCNA1, KCNA3, KCNA4, KCNC2, KCNIP3,
KCNQ2, LRRTM1, NEFL, NEFM, NRP1, PACSIN1, PNOC, PRKCZ, PTK2B,
ROBO2, SCN1B, SCN2A, SCN8A, SERPINF1, SLC17A7, STXBP1, SYN1,
SYNJ1, SYP, SYT1, UNC13A, VAMP1
3.96 1.99e-11
Axon hillock 3 4 CCK, PRKCZ, SERPINF1 18.80 9.40e-03
Axon part 27 71 AP1S1, AP3S1, BLOC1S2, CCK, CHRM1, DAGLA, DGKI, ELK1, KCNA1,
KCNC2, KCNIP3, KCNQ2, NEFL, PACSIN1, PNOC, PRKCZ, ROBO2,
SCN1B, SCN2A, SCN8A, SERPINF1, STXBP1, SYN1, SYNJ1, SYP, SYT1,
VAMP1
4.00 2.42e-07
Axon terminus 16 35 AP1S1, CCK, CHRM1, DGKI, ELK1, KCNA1, KCNC2, KCNIP3, PACSIN1,
PNOC, STXBP1, SYN1, SYNJ1, SYP, SYT1, VAMP1
5.40 4.44e-06
Blood circulation 30 138 ATP1A3, ATP2B1, CACNA1G, CACNA1H, CACNA2D1, CACNB1, CACNB2,
CACNG2, CACNG3, CHRM1, CLIC2, DRD1, EHD3, FGF12, GSK3A,
HMGCR, ITGB1BP1, KCND3, KCNIP1, KCNIP3, KCNIP4, KCNK1, NCALD,
OPRL1, PPARG, SCN1B, SCN2B, SCN3B, STC1, TRHDE
1.78 6.23e-03
Calcium channel complex 10 26 CACNA1G, CACNA1H, CACNA1I, CACNA2D1, CACNB1, CACNB2, CACNG2,
CACNG3, MCU, PTPA
3.96 1.53e-03
Calcium ion binding 38 171 ACTN4, ANXA2, CABP1, CAMKK2, CDH10, CDH12, CDH18, CDH9, CDK5R1,
CLSTN3, CRTAC1, DGKB, DOC2A, EHD3, EPDR1, HPCA, KCNIP1,
KCNIP3, KCNIP4, MCTP1, NCALD, NELL1, PCDH19, PCDH8, PITPNM2,
PITPNM3, PPP3R1, PRSS3, RASGRP1, RCVRN, REPS2, RPH3A, SLC25A23,
SLIT1, SYT1, TBC1D9, TLL1, VSNL1
1.85 1.44e-03
Calcium ion transmem-
brane transporter
activity
11 37 ATP2B1, CACNA1G, CACNA1H, CACNA1I, CACNA2D1, CACNB1, CACNB2,
CACNG2, CACNG3, GRIN2A, MCU
2.68 8.89e-03
Channel activity 42 139 CACNA1G, CACNA1H, CACNA1I, CACNA2D1, CACNB1, CACNB2, CACNG2,
CACNG3, CLIC2, GABRA2, GABRA3, GABRB3, GABRG2, GABRG3, GLRA3,
GRIN2A, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2, KCND3, KCNIP1,
KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNK1, KCNQ2, KCNQ5, KCNS2,
KCNV1, MCU, NCALD, PTK2B, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A,
SLC17A7, TTYH3
2.87 2.44e-07
Chemical synaptic trans-
mission, postsynaptic
12 22 CDK5, CELF4, DGKI, GABRB3, GRIN2A, GSK3A, MAPK8IP2, MEF2C,
PRKCZ, PTK2B, RIMS1, SLC17A7
7.65 7.33e-06
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TABLE 4. Continued
GO Term Count Size Genes Odds ratio p value
Chloride channel
complex
8 19 CLIC2, GABRA2, GABRA3, GABRB3, GABRG2, GABRG3, GLRA3, TTYH3 4.60 2.33e-03
Cilium 23 88 ANKMY2, ARL6, C5orf30, CEP126, CEP41, CFAP221, DRD1, EHD3, GNAQ,
GPR83, GRK4, HK1, IQUB, KIF17, KIFAP3, LRRC6, MCHR1, NAPEPLD,
NME5, PRKAR1B, PRKAR2B, SSX2IP, WRAP73
2.27 1.39e-04
Circulatory system
process
30 138 ATP1A3, ATP2B1, CACNA1G, CACNA1H, CACNA2D1, CACNB1, CACNB2,
CACNG2, CACNG3, CHRM1, CLIC2, DRD1, EHD3, FGF12, GSK3A,
HMGCR, ITGB1BP1, KCND3, KCNIP1, KCNIP3, KCNIP4, KCNK1, NCALD,
OPRL1, PPARG, SCN1B, SCN2B, SCN3B, STC1, TRHDE
1.78 6.23e-03
Cyclic nucleotide biosyn-
thetic process
13 38 CAP2, ADCY1, RUNDC3A, DRD1, PTK2B, GNAL, GRM2, GSK3A, HPCA,
OPRL1
3.31 1.13e-03
Cyclic purine nucleotide
metabolic process
13 38 CAP2, ADCY1, RUNDC3A, DRD1, PTK2B, GNAL, GRM2, GSK3A, HPCA,
OPRL1
3.31 1.13e-03
Dendrite 43 160 AMIGO1, ARHGAP32, ARHGAP44, ARHGEF2, ATP1A3, BAIAP2, CCK, CDK5,
CDK5R1, CHL1, CHRM1, DGKI, DRP2, ELK1, FRMPD4, GABRA2, GLRA3,
GLRX2, GNAQ, GNG3, GRK4, GRM2, HPCA, INPP5F, KCNA1, KCNB2,
KCNC2, KCND3, KCNIP1, KCNIP3, KCNK1, PCDH8, PCSK2, PLK2, PNOC,
PRKAR2B, PRKCG, PTK2B, RCVRN, SLC12A5, SYN1, SYNPO, THY1
2.42 5.82e-06
Dendrite extension 4 7 CPNE5, RIMS1, SYT1, UNC13A 8.38 8.91e-03
Dopamine receptor sig-
naling pathway
5 9 DRD1, GNAL, GNAQ, GSK3A, VPS35 7.87 3.84e-03
GABA receptor activity 6 10 GABBR2, GABRA2, GABRA3, GABRB3, GABRG2, GABRG3 9.47 8.64e-04
GABA receptor complex 5 9 GABRA2, GABRA3, GABRB3, GABRG2, GABRG3 7.87 3.84e-03
Gamma-aminobutyric
acid signaling pathway
6 10 HTR4, GABRG3, GABRG2, GABRA3, GABRA2, GABBR2 9.47 8.64e-04
Glutamate receptor sig-
naling pathway
13 28 ATP1A3, CACNG2, CACNG3, CDK5R1, GNAQ, GRIN2A, GRM2, GRM5,
HOMER1, MAPK8IP2, MEF2C, PTK2B, RASGRF1
5.53 2.93e-05
Glutamate secretion 7 15 CCK, GRM2, RIMS1, SLC17A7, SNAP25, STXBP1, SYT1 5.53 2.14e-03
Growth cone 13 41 CDK5, CDK5R1, CRTAC1, GAP43, LRRTM1, NEFL, NGEF, NRP1, PTK2B,
RASGRF1, SNAP25, THY1, TIAM2
2.95 2.48e-03
Intracellular protein
transport
46 237 AKAP5, ANXA2, AP1S1, AP2S1, AP3S1, ARHGEF2, ARL6, ATG4B, BAG4,
BAP1, BID, CABP1, CDK5, CDK5R1, CHML, CHRM1, DRD1, EHD3,
FBXW7, GDAP1, GNAQ, GSK3A, HPCA, ITGB1BP1, KCNB2, KCNIP3,
MAPK14, NAPB, NAPG, OAZ2, PPP3R1, RAB8B, RANBP1, REEP2, RFTN1,
RIMS1, RPH3A, RTN2, SSX2IP, TBC1D9, TMEM30A, TOMM34, TOMM70,
UBR5, VPS35, VPS36
1.56 8.18e-03
Ion channel complex 46 96 AMIGO1, CACNA1G, CACNA1H, CACNA1I, CACNA2D1, CACNB1, CACNB2,
CACNG2, CACNG3, CLIC2, DPP6, GABRA2, GABRA3, GABRB3, GABRG2,
GABRG3, GLRA3, GRIN2A, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2,
KCND3, KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNK1, KCNQ2,
KCNQ5, KCNS2, KCNV1, MCU, OLFM2, OLFM3, PTK2B, PTPA, SCN1B,
SCN2A, SCN2B, SCN3B, SCN8A, SNAP25, TTYH3
6.24 3.15e-16
Ionotropic glutamate re-
ceptor signaling
pathway
4 7 ATP1A3, CDK5R1, GRIN2A, PTK2B 8.38 8.91e-03
Main axon 9 25 CCK, DAGLA, KCNA1, KCNC2, KCNQ2, ROBO2, SCN1B, SCN2A, SCN8A 3.56 4.44e-03
Mitochondrial outer
membrane
permeabilization
4 7 BID, BLOC1S2, GSK3A, PPP3R1 8.38 8.91e-03
Mitochondrial outer
membrane permeabili-
zation involved in pro-
grammed cell death
4 7 BID, BLOC1S2, GSK3A, PPP3R1 8.38 8.91e-03
(continued)
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TABLE 4. Continued
GO Term Count Size Genes Odds ratio p value
Modulation of synaptic
transmission
27 78 BAIAP2, BTBD9, CA7, CDK5, CELF4, CLSTN3, DGKI, DRD1, GFAP, GRIN2A,
GRM2, GRM5, LRRTM1, LRRTM2, MAPK8IP2, MEF2C, PLK2, PRKCZ,
PTK2B, RASGRF1, RIMS1, SNAP25, STXBP1, SYN1, SYP,
3.44 2.13e-06
SYT1, UNC13A
Neurofilament 4 6 INA, NEFL, NEFM, NRP1 12.60 4.28e-03
Neuron part 107 379 ACTL6B, ACTN4, ADGRB1, AMIGO1, AMPH, AP1S1, AP3S1, ARHGAP32,
ARHGAP44, ARHGEF2, ATL1, ATP1A3, ATP2B1, BAIAP2, BLOC1S2,
CABP1, CADPS, CADPS2, CCK, CDK5, CDK5R1, CHL1, CHRM1, CPNE5,
CRTAC1, DAGLA, DDN, DGKI, DLGAP1, DOC2A, DRP2, ELK1, ENC1,
FRMPD4, GABBR2, GABRA2, GABRG2, GAP43, GLRA3, GLRX2, GNAQ,
GNG3, GRIN2A, GRK4, GRM2, GRM5, HOMER1, HPCA, ICA1, INPP5F,
KCNA1, KCNA3, KCNA4, KCNB2, KCNC2, KCND3, KCNIP1, KCNIP3,
KCNK1, KCNQ2, LIMK1, LRRTM1, MAPK8IP2, NAPEPLD, NEFL, NEFM,
NGEF, NRP1, NRSN2, NRXN3, OPRL1, PACSIN1, PCDH8, PCSK2, PDE1B,
PIP5K1C, PLK2, PNOC, PRKAR2B, PRKCG, PRKCZ, PTK2B, RAP1GAP2,
RASGRF1, RBFOX3, RCVRN, RIMS1, ROBO2, RPH3A, SCN1B, SCN2A,
SCN8A, SERPINF1, SLC12A5, SLC17A7, SNAP25, STXBP1, SV2B, SYN1,
SYNJ1, SYNPO, SYP, SYT1, THY1, TIAM2, UNC13A, VAMP1
2.81 2.92e-15
Neuron projection 90 294 ACTN4, AMIGO1, AP1S1, AP3S1, ARHGAP32, ARHGAP44, ARHGEF2, ATL1,
ATP1A3, ATP2B1, BAIAP2, BLOC1S2, CCK, CDK5, CDK5R1, CHL1, CHRM1,
CPNE5, CRTAC1, DAGLA, DDN, DGKI, DOC2A, DRP2, ELK1, FRMPD4,
GABBR2, GABRA2, GABRG2, GAP43, GLRA3, GLRX2, GNAQ, GNG3,
GRIN2A, GRK4, GRM2, GRM5, HOMER1, HPCA, INPP5F, KCNA1, KCNA3,
KCNA4, KCNB2, KCNC2, KCND3, KCNIP1, KCNIP3, KCNK1, KCNQ2,
LIMK1, LRRTM1, NEFL, NEFM, NGEF, NRP1, OPRL1, PACSIN1, PCDH8,
PCSK2, PLK2, PNOC, PRKAR2B, PRKCG, PRKCZ, PTK2B, RAP1GAP2,
RASGRF1, RCVRN, ROBO2, RPH3A, SCN1B, SCN2A, SCN8A, SERPINF1,
SLC12A5, SLC17A7, SNAP25, STXBP1, SV2B, SYN1, SYNJ1, SYNPO, SYP,
SYT1, THY1, TIAM2, UNC13A, VAMP1
3.16 3.62e-15
Neuron projection
morphogenesis
33 157 ADCY1, ADGRB1, AMIGO1, ATL1, BAIAP2, CCK, CDK5, CDK5R1, CHL1,
CHN1, CPNE5, GAP43, HPRT1, ID1, LIMK1, MAPK8IP2, NEFL, NGEF,
NRP1, NRXN3, NTN4, PACSIN1, PRKCZ, RBFOX2, RIMS1, ROBO2, SCN1B,
SLIT1, STXBP1, SYT1, THY1, UNC13A, ZNF280B
1.71 7.27e-03
Neuron remodeling 3 4 GNAQ, NTN4, RND1 18.80 9.40e-03
Neuronal cell body 36 130 AMIGO1, ARHGEF2, ATP2B1, BAIAP2, CCK, CDK5, CDK5R1, CPNE5, DDN,
DGKI, DRP2, ELK1, ENC1, GABRA2, GLRA3, GLRX2, GRK4, HPCA,
INPP5F, KCNA1, KCNB2, KCNC2, KCNK1, MAPK8IP2, NRP1, NRSN2,
PCSK2, PDE1B, PNOC, PRKAR2B, PRKCZ, PTK2B, RBFOX3, SERPINF1,
SLC12A5, SYNPO
2.50 1.69e-05
Neuron-neuron synaptic
transmission
16 46 CA7, CDK5, CLSTN3, DGKI, DRD1, GABRG2, GLRA3, GRM2, GRM5, MAP-
K8IP2, MEF2C, PTK2B, SLC17A7, STXBP1, SYT1, UNC13A
4.10 5.04e-05
Neurotransmitter receptor
activity
9 23 CHRM1, DRD1, GABRA2, GABRA3, GABRB3, GABRG2, GLRA3, GRIN2A,
PTK2B
4.07 2.23e-03
Neurotransmitter
secretion
16 46 CDK5, RPH3A, RIMS1, UNC13A, PIP5K1C, MEF2C, SNAP25, STXBP1, SYN1,
SYT1, DOC2A, CADPS, SYNJ1, DGKI, CADPS2, NRXN3
3.41 2.49e-04
Node of Ranvier 4 6 KCNQ2, SCN1B, SCN2A, SCN8A 12.60 4.28e-03
Nonmotile primary
cilium
9 25 C5orf30, DRD1, GNAQ, GPR83, GRK4, KIF17, KIFAP3, MCHR1, NAPEPLD 3.56 4.44e-03
Postsynapse 39 121 ADGRB1, ARHGAP32, ARHGAP44, ATP1A3, BAIAP2, CABP1, CADPS2,
CDK5, CDK5R1, CHRM1, CLSTN3, DGKI, DLGAP1, DRP2, FRMPD4,
GABBR2, GABRA2, GABRA3, GABRB3, GABRG2, GABRG3, GAP43, GLRA3,
GRIN2A, GRM5, GSK3A, HOMER1, HPCA, KCNC2, LRRTM1, LRRTM2,
MAPK8IP2, MEF2C, PCDH8, PRKAR2B, PTK2B, SLC17A7, SYN1, SYNPO
3.14 9.97e-08
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TABLE 4. Continued
GO Term Count Size Genes Odds ratio p value
Postsynaptic density 17 54 ADGRB1, ARHGAP32, BAIAP2, CABP1, CDK5, CDK5R1, CHRM1, DLGAP1,
DRP2, GAP43, GRIN2A, GRM5, HOMER1, MAPK8IP2, PTK2B, SYN1,
SYNPO
2.94 6.16e-04
Potassium channel
activity
16 39 KCNA1, KCNA3, KCNA4, KCNB2, KCNC2, KCND3, KCNIP1, KCNIP3,
KCNIP4, KCNJ16, KCNJ6, KCNK1, KCNQ2, KCNQ5, KCNS2, KCNV1
4.46 2.41e-05
Potassium ion transport 25 71 AMIGO1, ATP1A3, CAB39, DPP10, DPP6, DRD1, KCNA1, KCNA3, KCNA4,
KCNB2, KCNC2, KCND3, KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6,
KCNK1, KCNQ2, KCNQ5, KCNS2, KCNV1, PTK2B, SLC12A5, SLC12A8
3.52 3.60e-06
Presynapse 29 84 AMPH, AP1S1, CADPS, CADPS2, CCK, CDK5, DGKI, DOC2A, GABRA2,
GRIN2A, GRM2, ICA1, KCNA1, KCNC2, NRXN3, PCDH8, PIP5K1C, RIMS1,
RPH3A, SLC17A7, SNAP25, STXBP1, SV2B, SYN1, SYNJ1, SYP, SYT1,
UNC13A, VAMP1
3.44 9.43e-07
Primary cilium 11 37 ARL6, C5orf30, CEP41, DRD1, GNAQ, GPR83, GRK4, KIF17, KIFAP3,
MCHR1, NAPEPLD
2.68 8.98e-03
Purine nucleotide biosyn-
thetic process
16 59 ADCY1, AKAP5, ATP5A1, CAP2, DRD1, GABBR2, GNAL, GRM2, GSK3A,
HPCA, HPRT1, NME5, OPRL1, PTK2B, RCVRN, RUNDC3A
2.37 4.90e-03
Regulation of alternative
mRNA splicing, via
spliceosome
5 10 CELF3, CELF4, RBFOX1, RBFOX2, RBFOX3 6.30 6.82e-03
Regulation of calcium
ion-dependent
exocytosis
9 24 CACNA1G, CACNA1I, CDK5, DOC2A, RIMS1, RPH3A, STXBP1, SYN1, SYT1 3.80 3.23e-03
Regulation of ion trans-
membrane transport
46 125 ACTN4, AMIGO1, CAB39, CACNA1G, CACNA1H, CACNA1I, CACNA2D1,
CACNB1, CACNB2, CACNG2, CACNG3, CLIC2, DPP10, DPP6, DRD1,
EHD3, FGF12, HOMER1, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2,
KCND3, KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNQ2, KCNQ5,
KCNS2, KCNV1, MAPK8IP2, MEF2C, MMP9, OPRL1, PTK2B, PTPN3,
RASGRF1, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A, THY1
3.91 4.16e-11
Regulation of neurotrans-
mitter levels
23 64 CADPS, CADPS2, CDK5, DAGLA, DGKI, DOC2A, DRD1, GABRA2, GFAP,
MEF2C, NRXN3, PDE1B, PIP5K1C, RIMS1, RPH3A, SLC17A7, SNAP25,
STXBP1, SV2B, SYN1, SYNJ1, SYT1, UNC13A
3.63 5.98e-06
Regulation of nucleotide
biosynthetic process
13 37 ADCY1, AKAP5, CAP2, DRD1, GABBR2, GNAL, GRM2, GSK3A, HPCA,
OPRL1, PTK2B, RCVRN, RUNDC3A
3.45 8.49e-04
Regulation of nucleotide
metabolic process
15 49 ADCY1, AKAP5, CAP2, DRD1, GABBR2, GNAL, GRM2, GSK3A, HPCA,
OPRL1, PTK2B, RCVRN, RUNDC3A, SLC25A23, TIGAR
2.81 1.76e-03
Regulation of purine nu-
cleotide biosynthetic
process
13 39 CAP2, ADCY1, RUNDC3A, DRD1, PTK2B, GNAL, GRM2, GSK3A, HPCA,
OPRL1
3.18 1.49e-03
Regulation of synapse
assembly
10 27 ADGRB1, ADGRB2, AMIGO1, CLSTN3, LRRTM1, LRRTM2, MEF2C, NRXN3,
ROBO2, SLIT1
3.73 2.17e-03
Regulation of synapse
organization
11 36 ADGRB1, ADGRB2, AMIGO1, CLSTN3, FRMPD4, LRRTM1, LRRTM2, MEF2C,
NRXN3, ROBO2, SLIT1
2.79 7.18e-03
Regulation of synapse
structure or activity
11 36 ADGRB1, ADGRB2, AMIGO1, CLSTN3, FRMPD4, LRRTM1, LRRTM2, MEF2C,
NRXN3, ROBO2, SLIT1
2.79 7.18e-03
Regulation of synaptic
plasticity
18 43 BAIAP2, CDK5, DGKI, DRD1, GFAP, GRIN2A, GRM5, LRRTM1, LRRTM2,
MEF2C, PLK2, PRKCZ, PTK2B, RASGRF1, SNAP25, STXBP1, SYP, UNC13A
4.63 5.26e-06
Regulation of transmem-
brane transport
47 129 ACTN4, AMIGO1, CAB39, CACNA1G, CACNA1H, CACNA1I, CACNA2D1,
CACNB1, CACNB2, CACNG2, CACNG3, CLIC2, DPP10, DPP6, DRD1,
EHD3, FGF12, HOMER1, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2,
KCND3, KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNQ2, KCNQ5,
KCNS2, KCNV1, MAPK8IP2, MEF2C, MMP9, OAZ2, OPRL1, PTK2B,
PTPN3, RASGRF1, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A, THY1
3.86 3.79e-11
(continued)
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TABLE 4. Continued
GO Term Count Size Genes Odds ratio p value
Regulation of vesicle-me-
diated transport
27 120 ACTN4, ANXA2, AP2S1, BTBD9, CACNA1G, CACNA1I, CADPS2, CDK5,
DOC2A, INPP5F, LRRTM1, LRRTM2, NRP1, PACSIN1, PPARG, PRKCG,
RAB27B, RIMS1, RINT1, RPH3A, SCFD1, SNAP91, STXBP1, SYN1, SYT1,
TBC1D9, VSNL1
1.86 5.74e-03
Somatodendritic
compartment
54 205 AMIGO1, ARHGAP32, ARHGAP44, ARHGEF2, ATP1A3, ATP2B1, BAIAP2,
CCK, CDK5, CDK5R1, CHL1, CHRM1, CPNE5, DDN, DGKI, DRP2, ELK1,
ENC1, FRMPD4, GABRA2, GLRA3, GLRX2, GNAQ, GNG3, GRK4, GRM2,
HPCA, INPP5F, KCNA1, KCNB2, KCNC2, KCND3, KCNIP1, KCNIP3,
KCNK1, MAPK8IP2, NRP1, NRSN2, PCDH8, PCSK2, PDE1B, PLK2, PNOC,
PRKAR2B, PRKCG, PRKCZ, PTK2B, RBFOX3, RCVRN, SERPINF1,
SLC12A5, SYN1, SYNPO, THY1
2.39 6.48e-07
Synapse 68 222 ADGRB1, AMPH, AP1S1, ARHGAP32, ARHGAP44, ATP1A3, ATP2B1, BAIAP2,
CABP1, CADPS, CADPS2, CCK, CDK5, CDK5R1, CHRM1, CLSTN3, DDN,
DGKI, DLGAP1, DOC2A, DRP2, FRMPD4, GABBR2, GABRA2, GABRA3,
GABRB3, GABRG2, GABRG3, GAP43, GLRA3, GRIN2A, GRM2, GRM5,
GSK3A, HOMER1, HPCA, ICA1, KCNA1, KCNC2, KCNK1, LRRTM1,
LRRTM2, MAPK8IP2, MEF2C, NRXN3, OLFM2, OLFM3, PACSIN1, PCDH8,
PHACTR1, PIP5K1C, PRKAR2B, PRKCG, PTK2B, RIMS1, RPH3A, SLC17A7,
SNAP25, STXBP1, SV2B, SYN1, SYNJ1, SYNPO, SYP, SYT1, UNC13A,
VAMP1, WASF1
3.05 1.43e-11
Synapse assembly 12 39 ADGRB1, ADGRB2, AMIGO1, CDK5, CLSTN3, DRD1, LRRTM1, LRRTM2,
MEF2C, NRXN3, ROBO2, SLIT1
2.82 4.75e-03
Synapse organization 18 67 ADGRB1, ADGRB2, AMIGO1, CACNB1, CACNB2, CACNG2, CDK5, CLSTN3,
DRD1, DRP2, FRMPD4, LRRTM1, LRRTM2, MEF2C, NRXN3, ROBO2,
SLIT1, UNC13A
2.34 3.25e-03
Synapse part 63 190 ADGRB1, AMPH, AP1S1, ARHGAP32, ARHGAP44, ATP1A3, ATP2B1, BAIAP2,
CABP1, CADPS, CADPS2, CCK, CDK5, CDK5R1, CHRM1, CLSTN3, DDN,
DGKI, DLGAP1, DOC2A, DRP2, FRMPD4, GABBR2, GABRA2, GABRA3,
GABRB3, GABRG2, GABRG3, GAP43, GLRA3, GRIN2A, GRM2, GRM5,
GSK3A, HOMER1, HPCA, ICA1, KCNA1, KCNC2, LRRTM1, LRRTM2, MAP-
K8IP2, MEF2C, NRXN3, OLFM2, PCDH8, PIP5K1C, PRKAR2B, PRKCG,
PTK2B, RIMS1, RPH3A, SLC17A7, SNAP25, STXBP1, SV2B, SYN1, SYNJ1,
SYNPO, SYP, SYT1, UNC13A, VAMP1
3.41 1.79e-12
Synaptic membrane 35 89 ARHGAP32, ATP2B1, CABP1, CADPS2, CDK5, CHRM1, CLSTN3, DDN, DGKI,
DLGAP1, DRP2, GABBR2, GABRA2, GABRA3, GABRB3, GABRG2,
GABRG3, GLRA3, GRIN2A, GRM2, HOMER1, KCNA1, KCNC2, LRRTM1,
LRRTM2, OLFM2, PCDH8, PRKCG, RIMS1, SNAP25, SYNJ1, SYNPO, SYP,
SYT1, UNC13A
4.28 1.28e-08
Synaptic signaling 63 182 AKAP5, AMPH, BAIAP2, BTBD9, CA7, CACNA1G, CACNB1, CACNB2, CADPS,
CADPS2, CDK5, CELF4, CHRM1, CLSTN3, DGKI, DLGAP1, DOC2A, DRD1,
EGR3, FGF12, GABBR2, GABRB3, GABRG2, GFAP, GLRA3, GPR176,
GRIN2A, GRM2, GRM5, GSK3A, HOMER1, HTR4, KCNA1, KCNQ2, KCNQ5,
LRRTM1, LRRTM2, MAPK8IP2, MEF2C, NRXN3, OPRL1, PCDH8,
PIP5K1C, PLK2, PNOC, PRKCG, PRKCZ, PTK2B, RASGRF1, RIMS1,
RPH3A, SCN1B, SCN2B, SLC12A5, SLC17A7, SNAP25, SNAP91, STXBP1,
SYN1, SYNJ1, SYP, SYT1, UNC13A
3.65 1.90e-13
Synaptic transmission,
glutamatergic
12 26 CDK5, CLSTN3, DGKI, DRD1, GRM2, GRM5, MAPK8IP2, MEF2C, PTK2B,
SLC17A7, SYT1, UNC13A
5.46 6.45e-05
Synaptic vesicle 14 37 AMPH, DGKI, DOC2A, GABRA2, GRIN2A, ICA1, RPH3A, SLC17A7, SNAP25,
SV2B, SYN1, SYP, SYT1, VAMP1
3.88 2.21e-04
Synaptic vesicle
endocytosis
6 10 CDK5, BTBD9, PIP5K1C, PACSIN1, SYT1, SYNJ1 9.47 8.64e-04
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(p¼ 0.001), APRT (p¼ 0.001), DGUOK (p¼ 0.007),
ENTPD3 (p¼ 0.02), NME1 (p¼ 0.03), NME3 (p¼ 0.01),
NME7 (p¼ 0.007), and POLR3B (p¼ 0.003) were signifi-
cantly deregulated in sFTLD-TDP (Fig. 5).
Protein Expression Levels of Selected Genes
Expression levels of 14 proteins not related to mitochon-
dria and energy metabolism were assessed. C9ORF72 protein
levels were significantly decreased in sFTLD-TDP (p¼ 0.01).
However, TDP-43 levels were increased in sFTLD-TDP
(p¼ 0.02) (Fig. 6). Significant reduction of VGAT (p¼ 0.04)
and GAD1 (p¼ 0.02) levels occurred in sFTLD-TDP. A sig-
nificant reduction was found in GABRD protein levels
(p¼ 0.02), but no changes were detected in synaptophysin
(SYP), NMDAR2A, GABAARB2, calbindin-28K (CALB1),
and SNAP25 levels in sFTLD-TDP. GFAP levels showed a
TABLE 4. Continued
GO Term Count Size Genes Odds ratio p value
Synaptic vesicle
exocytosis
13 34 CADPS, CADPS2, CDK5, DOC2A, PIP5K1C, RIMS1, RPH3A, SNAP25,
STXBP1, SYN1, SYNJ1, SYT1, UNC13A
3.94 3.28e-04
Synaptic vesicle
maturation
4 5 UNC13A, SYP, STXBP1, SLC17A7 25.20 1.60e-03
Synaptic vesicle
membrane
11 22 AMPH, DOC2A, GABRA2, ICA1, RPH3A, SLC17A7, SV2B, SYN1, SYP, SYT1,
VAMP1
6.36 5.22e-05
Synaptic vesicle priming 5 7 CADPS, CADPS2, SNAP25, STXBP1, SYNJ1 15.80 8.14e-04
Synaptic vesicle
recycling
6 10 CDK5, BTBD9, PIP5K1C, PACSIN1, SYT1, SYNJ1 9.47 8.64e-04
Synaptic vesicle transport 17 42 AP3S1, BLOC1S2, BTBD9, CADPS, CADPS2, CDK5, DOC2A, PACSIN1,
PIP5K1C, RIMS1, RPH3A, SNAP25, STXBP1, SYN1, SYNJ1, SYT1, UNC13A
4.36 1.66e-05
Terminal bouton 9 17 AP1S1, CCK, KCNC2, STXBP1, SYN1, SYNJ1, SYP, SYT1, VAMP1 7.14 1.47e-05
Transport vesicle 25 103 AMPH, AP1S1, AP3S1, CNST, DDHD2, DGKI, DOC2A, GABRA2, GRIN2A,
ICA1, NCALD, NRSN2, PCSK2, RAB27B, RPH3A, SCG3, SLC17A7, SNAP25,
STEAP2, SV2B, SYN1, SYP, SYT1, TMEM30A, VAMP1
2.06 2.69e-03
Voltage-gated ion chan-
nel activity
30 65 CACNA1G, CACNA1H, CACNA1I, CACNA2D1, CACNB1, CACNB2, CACNG2,
CACNG3, CLIC2, KCNA1, KCNA3, KCNA4, KCNB2, KCNC2, KCND3,
KCNIP1, KCNIP3, KCNIP4, KCNJ16, KCNJ6, KCNK1, KCNQ2, KCNQ5,
KCNS2, KCNV1, SCN1B, SCN2A, SCN2B, SCN3B, SCN8A
5.64 1.91e-10
FIGURE 3. mRNA expression levels of selected deregulated genes in frontal cortex area 8 of sFTLD-TDP and controls assessed
with TaqMan RT-qPCR assays. Genes coding for (A) proteins involved in toxic aggregates of FTLD variants and GFAP: (B, C)
cytoskeleton and structural components. Significant levels set at *p<0.05, **p<0.01, and ***p<0.001.
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nonsignificant increase in sFTLD-TDP cases when compared
with controls (Fig. 6).
Total TAU, 4R-TAU and 3R-TAU
To further analyze cytoskeletal anomalies, the expres-
sion levels of total TAU, 3R-TAU, and 4R-TAU were
assessed using forward SYBR primer and reverse primer spe-
cific probes. Total Tau, 3R-TAU, and 4R-TAU mRNA ex-
pression levels were similar in sFTLD-TDP cases when
compared with controls. In this line, 4R/3R ratio was pre-
served in sFTLD cases. Protein expression was studied with
Western blotting. Total TAU protein levels were similar in
sFTLD-TDP and controls and the ratio 4R/3R was not modi-
fied. Finally, no evidence of increased tau phosphorylation, as
revealed with the phospho-tauThr181 antibody was found in
sFTLD-TDP (Fig. 7).
Mitochondrial Alterations
Genes Coding for Mitochondrial Subunits and Energy
Metabolism
The expression of 37 genes was assessed by RT-qPCR;
27 of them were deregulated in sFTLD-TDP. Downregulated
genes encoded subunits of the electron transport chain (ETC)
complexes I: NDUFA2 (p¼ 0.02), NDUFA5 (p¼ 0.05),
NDUFA10 (p¼ 0.016), NDUFAF2 (p¼ 0.02), NDUFAF6
(p¼ 0.04), NDUFB5 (p¼ 0.016), NDUFB8 (p¼ 0.017), and
NDUFB10 (p¼ 0.025); subunits of complex IV: COX7A2L
FIGURE 4. mRNA expression levels of selected deregulated genes identified by microarray analysis in frontal cortex area 8 of
sFTLD-TDP and controls assessed by TaqMan RT-qPCR assays are coding for glutamatergic and GABAergic-related genes and
corresponding ionotropic and metabotropic receptors, as well as synaptic cleft proteins and neurotransmission vesicles system.
Significant levels set at *p<0.05, **p<0.01, and ***p<0.001.
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(p¼ 0.02) and COA6 (p¼ 0.02); and complex V: ATP5O
(p¼ 0.015), ATP5A1 (p¼ 0.03), and ATP5B (p¼ 0.04). In ad-
dition, several genes involved in energy metabolism were
downregulated in sFTLD-TDP including ATP2B3 (p¼ 0.03),
ATP2B4 (p¼ 0.04), ATP6D (p¼ 0.02), ATP6V1A (p¼ 0.002),
FASTKD2 (p¼ 0.007), MCU (p¼ 0.045), MICU3 (p¼ 0.01),
MTIF2 (p¼ 0.006), MTX3 (p¼ 0.03), RMND1 (p¼ 0.005),
SLC25A1 (p¼ 0.01), SLC25A11 (p¼ 0.03), SLC25A23
(p¼ 0.03), and TOMM70 (p¼ 0.001) (Fig. 8A).
Mitochondria Protein Levels in Mitochondria-enriched
Fractions
Decreased levels of NDUFB10 were found in sFTLD-
TDP (p¼ 0.04), but not of NDUFB8, NDUFS8, NDUFA10.
Protein levels of SDHB, a component of ETC complex II,
were not modified in sFTLD-TDP. In contrast, UQCRC2, a
component of ETC complex III, was significantly increased in
sFTLD-TDP (p¼ 0.03). Levels of ATP5A were significantly
decreased (p¼ 0.04). MT-CO1 levels were significantly de-
creased in sFTLD-TDP (p¼ 0.01) but MT-ND1 expression
was preserved (Fig. 8B). In contrast to mRNA expression,
TOMM70 protein levels were not significantly altered in path-
ological cases when compared with controls.
Mitochondrial Enzymatic Activities in Mitochondrial
Enriched Fractions
The enzymatic activity of mitochondrial complexes I,
IV, and V was significantly reduced in sFTLD-TDP cases
when compared with controls (p¼ 0.04, p¼ 0.03, and
p¼ 0.05, respectively) (Fig. 8C).
DISCUSSION
Gene transcription profiles are analyzed in the frontal
cortex area 8 in sFTLD cases with typical neuropathology in-
cluding TDP-43-immunoreactive inclusions mainly in the
form of cortical neurites and intracytoplasmic inclusions.
Cases in this series had reduced TARDBP mRNA expression
and increased levels of TDP-43 protein, and reduced expres-
sion of C9Orf72 mRNA and protein. Opposite expression of
TDP mRNA and protein may be related to translational modi-
fications. These are further accompanied by posttranslational
modifications of TDP-43 (10). Decreased C9Orf72 mRNA
and protein was not expected and further studies are needed to
elucidate C9Orf72 loss of function in sFTLD-TDP not linked
to C9ORF72 mutations.
The present study using whole-transcriptome microar-
ray hybridization showed downregulation of several genes in
FIGURE 5. mRNA expression levels of selected deregulated genes identified by microarray analysis in frontal cortex area 8 of
sFTLD-TDP and controls assessed with TaqMan RT-qPCR assays coding for purines metabolism. Significant levels set at *p<0.05,
**p<0.01, and ***p<0.001.
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the frontal cortex area 8 in sFTLD-TDP clustered in pathways
involved in neurotransmission and synapsis, neuronal archi-
tecture, cytoskeleton of axons and dendrites, vesicle traffick-
ing, purine metabolism, mitochondria, and energy
metabolism. Microarray observations were further validated
by RT-qPCR of selected genes from predicted altered path-
ways after searching on Gene Ontology (GO) database, using
111 probes; the expression of 81 genes was significantly
deregulated in this cortical region in sFTLD-TDP when com-
pared with controls. Expression levels of 24 proteins were ana-
lyzed by Western blotting; levels of 8 proteins were altered in
sFTLD-TDP. Neurotransmission was markedly affected in
sFTLD-TDP involving downregulated gene expression of glu-
tamate decarboxylase, several types and subunits of ionotropic
and metabotropic glutamate and GABA receptors, neuronal
vesicular and soluble glutamate transporters, and various
synaptic proteins, together with loss of calbindin expression.
This provides robust support to preliminary observations
showing decreased numbers, amputation, and proximal swel-
lings of dendritic branches and loss of synaptic spine pyrami-
dal cells, and loss of calbindin-immunoreactive neurons and
atrophy of remaining neurons in layers II and III of the frontal
cortex in FTLD (24). Protein expression studies showing de-
creased levels of synaptic markers are also in line with previ-
ous observations demonstrating reduced levels of several
synaptic and presynaptic plasma membrane proteins in the
frontal cortex, but not in the posterior parietal cortex assessed
in parallel, in FTLD (25).
In contrast to the marked decrease in the expression of
cytoskeletal and synaptic markers, tau mRNA and protein lev-
els were preserved in the present series, and tau phosphoryla-
tion was not increased in sFTLD-TDP. This is in contrast with
FIGURE 6. Gel electrophoresis and Western blotting of proteins involved in toxic aggregates in FTLD, GABAergic, and
glutamatergic neurotransmission systems, synaptic vesicles, cytoskeleton, neuroinflammation, and mitochondria. Significant
levels set at *p<0.05, **p<0.01, and ***p<0.001.
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early reports pointing to decreased tau protein levels in FTLD
with ubiquitin inclusions (presumably FTLD-TDP), which
suggested that FTLD-U may be a novel “inverse” tauopathy
because of the reduced levels of tau (26, 27). Reduced
tau mRNA and protein levels have been reported in FTLD-
TDP linked to GRN mutations but not in other FTLD-TDP
subtypes including sporadic FTLD-TDP and FTLD-TDP-
C9ORF72 (28).
Mitochondrial alterations compromise mRNA expres-
sion of several subunits of the mitochondrial complexes.
Moreover, they are accompanied by altered protein expression
of several subunits and with reduced activity of complexes I,
IV, and V in sFTLD-TDP. Importantly, in addition to mito-
chondrial subunits encoded by genomic DNA, expression lev-
els of MT-CO1 encoded by mitochondrial DNA are reduced
in sFTLD-TDP. Therefore, mitochondrial alterations in
sFTLD-TDP have both genomic and mitochondrial compo-
nents. Other genes involved in energy metabolism are downre-
gulated as well, thus indicating functional energy metabolism
failure in sFTLD-TDP. Gene-specific mitochondrial dysfunc-
tion has been described in human fibroblasts bearing
mutations in TARDBP and C9ORF72 (29). Mitochondrial dys-
function has also been documented in a transgenic knock-in
mouse model for TDP-43 (30). Therefore, mitochondrial alter-
ations seem to be common to different forms of sFTLD-TDP
and fFTLD-TDP.
Purines and pyrimidines are components of a large num-
ber of key molecules. The primary purines adenine and guano-
sine, and pyrimidines cytosine, thymidine, and uracyl, are the
core of DNA, RNA, nucleosides, and nucleotides involved in
energy transfer (ATP, GTP) and coenzymes (NADH,
FADH2) (31, 32). Alterations in the expression of genes
encoding enzymes of purine metabolism may interfere with
numerous metabolic processes in sFTLD-TDP.
It can be argued that differences in the percentage of
neurons, astrocytes, oligodendroglia, and microglia lie beyond
distinct patterns of gene expression, protein levels, and mito-
chondrial enzymatic activities in sFTLD-TDP. Certainly, neu-
ron loss, spongiosis in the upper cortical layers and variable
astrocytic gliosis are typical morphological alterations in
sFTLD-TDP (1–3). Present findings complement morphologi-
cal observations by biochemical data that identify damage of
particular components of vital molecular pathways and essen-
tial modulators of synaptic transmission.
Previous studies have shown differential gene
expression in frontal cortex between 6 cases of FTLD-U
FIGURE 7. (A) mRNA expression levels of total TAU, 3R-TAU, and 4R-TAU in the frontal cortex area 8 in control and sFTLD-TDP.
No significant differences are observed and the ratio 4R/3R is similar in sFTLD and controls. (B) Similarly, no differences in TAU
protein expression and 4R/3R are seen in sFTLD-TDP cases and controls. Phospho-tau levels, as revealed with the phospho-tau-
specific Thr181 antibody, are similar in control and sFTLD-TDP.
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(FTLD-TDP), 3 of them bearing GRN mutations, and 4
FTLD-MND (linked to motor neuron disease) cases. RT-
qPCR validated the deregulation of dynein, annexinA2, and
myeloid differentiation primary response in FTLD-U (14).
Another study examined 7 FTLD-U cases linked to GRN
mutations and 10 FTLD-U cases without GRN mutations (15).
FIGURE 8. (A) mRNA expression levels of selected deregulated genes identified by microarray analysis in the frontal cortex area
8 of sFTLD-TDP and controls assessed with TaqMan RT-qPCR assays coding for subunits of the mitochondrial respiratory chain
and proteins linked to energy metabolism. (B) Protein levels in control and sFTLD-TDP of subunits encoded by genomic DNA of
mitochondrial complexes I (NDUFA10, NDUFB10, NDUFS8, NDUFB8), II (SDHB), III (UQCRC2), and V (ATP5A); encoded by
mitochondrial DNA of complex I (MT-ND1) and complex IV (MTCO1); and TOMM10 normalized with voltage-dependent anion
channel (VDAC). Diagrams show quantitative values of all assessed cases. (C) Mitochondrial enzymatic activities in complex I, II,
IV, and V in control and FTLD. All the mitochondrial activities are corrected with citrate synthase activity. Significant levels set at
*p<0.05, **p<0.01, and ***p<0.001.
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A distinct molecular phenotype was identified for GRNþ
FTLD-U when compared with GRN-FTLD-U subtypes. Vali-
dation by RT-qPCR was assessed for 16 genes; deregulated bi-
ological processes associated with GRN-FTLD-U were lipid
metabolism, MAPK signaling pathways, and transport (15). A
recent study in the cerebellum and frontal cortex in sALS and
ALS linked to C9ORF72 mutations has shown 57 genes in cer-
ebellum and 32 genes in frontal cortex abnormally expressed
in both c9ALS and sALS; however, the number of deregulated
genes in C9ORF72 sALS cases was double than in sALS
thus further suggesting differences between different forms of
ALS (19).
Comparison between present findings and our previous
observations in frontal cortex area 8 in sALS (18), using the
same methods, is worth stressing since most of downregulated
genes in sFTLD-TDP are upregulated in the frontal cortex
area 8 in sALS cases without dementia (18). This suggests a
primary response to synaptic and neurotransmission disturban-
ces of frontal cortex area 8 at preclinical stages of frontal de-
generation in sALS. Reduced expression of genes encoding
actin, actin-related members, kinesin, and microtubule-
associated protein further supports cytoskeletal damage in
sALS and sFTLD-TDP.
Conclusions
Whole transcriptome arrays and bioinformatics process-
ing followed by RT-qPCR expression of 111 genes shows
deregulation of 81 genes involved in cytoskeleton and neuron
structure, neurotransmitters, receptors, transporters and synap-
tic proteins, components of mitochondrial function and energy
metabolism, enzymes involved in purine metabolism and
RNA splicing in sFTLD-TDP. Western blotting of selected
proteins further supports alterations of these pathways at trans-
lational level. Finally, altered mitochondrial activity of several
mitochondrial complexes is demonstrated by enzymatic
assays.
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